These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37927811)

  • 41. Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
    Sun YU; Nishino H; Sugisawa N; Yamamoto J; Hamada K; Zhu G; Lim HI; Hoffman RM
    Anticancer Res; 2020 Nov; 40(11):6083-6091. PubMed ID: 33109546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs.
    Hu J; Cheung NK
    Int J Cancer; 2009 Apr; 124(7):1700-6. PubMed ID: 19089915
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of Recombinant Methioninase for Cancer Treatment.
    Hoffman RM; Tan Y; Li S; Han Q; Yagi S; Takakura T; Takimoto A; Inagaki K; Kudou D
    Methods Mol Biol; 2019; 1866():107-131. PubMed ID: 30725412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of PD-L1 Is Increased by Methionine Restriction Using Recombinant Methioninase in Human Colorectal Cancer Cells.
    Mizuta K; Kang BM; Han Q; Kubota Y; Morinaga S; Sato M; Bouvet M; Tome Y; Nishida K; Hoffman RM
    Cancer Genomics Proteomics; 2024; 21(4):395-398. PubMed ID: 38944421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
    Kubota Y; Han Q; Hozumi C; Masaki N; Yamamoto J; Aoki Y; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 May; 42(5):2567-2572. PubMed ID: 35489727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
    Sato M; Han Q; Mizuta K; Mori R; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    In Vivo; 2024; 38(3):1459-1464. PubMed ID: 38688589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergy of Rapamycin and Methioninase on Colorectal Cancer Cells Requires Simultaneous and Not Sequential Administration: Implications for mTOR Inhibition.
    Ardjmand D; Sato M; Han Q; Kubota Y; Mizuta K; Morinaga S; Hoffman RM
    Cancer Diagn Progn; 2024; 4(4):396-401. PubMed ID: 38962555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.
    Yamamoto J; Miyake K; Han Q; Tan Y; Inubushi S; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Homma Y; Matsuyama R; Chawla SP; Bouvet M; Singh SR; Endo I; Hoffman RM
    Cancer Lett; 2020 Nov; 492():174-184. PubMed ID: 32739322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels.
    Han Q; Hoffman RM
    In Vivo; 2021; 35(4):2171-2176. PubMed ID: 34182494
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates.
    Hoffman RM; Yang Z; Tan Y; Han Q; Li S; Yagi S
    Methods Mol Biol; 2019; 1866():211-229. PubMed ID: 30725418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic Drug.
    Choobin BB; Kubota Y; Han Q; Ardjmand D; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Diagn Progn; 2023; 3(6):655-659. PubMed ID: 37927805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
    Oshiro H; Tome Y; Kiyuna T; Yoon SN; Lwin TM; Han Q; Tan Y; Miyake K; Higuchi T; Sugisawa N; Katsuya Y; Park JH; Zang Z; Razmjooei S; Bouvet M; Clary B; Singh SR; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4667-4671. PubMed ID: 31519565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Combination of Methionine Restriction and Docetaxel Synergistically Arrests Androgen-independent Prostate Cancer But Not Normal Cells.
    Mizuta K; Mori R; Han Q; Morinaga S; Sato M; Kang BM; Bouvet M; Tome Y; Nishida K; Hoffman RM
    Cancer Diagn Progn; 2024; 4(4):402-407. PubMed ID: 38962551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant Engineering of L-Methioninase Using Two Different Promoter and Expression Systems and in vitro Analysis of Its Anticancer Efficacy on Different Human Cancer Cell Lines.
    Muharram MM
    Pak J Biol Sci; 2016; 19(3):106-114. PubMed ID: 29023047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3777-3783. PubMed ID: 39197933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
    Han Q; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1921-1926. PubMed ID: 33813397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts.
    Morinaga S; Han Q; Kubota Y; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Jun; 44(6):2359-2367. PubMed ID: 38821601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.